Gross Profit tvrtke Medicalgorithmics (MDG.WA) na dan 15. ožu 2026..
Medicalgorithmics Gross Profit
Gross Profit
0PLN
Zadnje ažuriranje: 15. ožu 2026.
Gross Profit tvrtke Medicalgorithmics iznosi 2026 0 PLN. Gross Profit tvrtke Medicalgorithmics iznosio je 2025 0 PLN. Pada za % manji u odnosu na prošlu godinu.
Povijest Medicalgorithmics Gross Profit
3 godine
10 godina
25 godina
Max
BRUTO MARGINA (%)
Date
BRUTO MARGINA (%)
1. sij 2011.
5.172,00 base
1. sij 2012.
6.364,00 base
1. sij 2013.
6.306,00 base
1. sij 2014.
4.633,00 base
1. sij 2015.
4.234,00 base
1. sij 2016.
1.757,00 base
1. sij 2017.
2.296,00 base
1. sij 2018.
1.680,00 base
1. sij 2019.
120,00 base
1. sij 2020.
−3.018,00 base
1. sij 2021.
7.949,00 base
1. sij 2022.
8.030,00 base
1. sij 2023.
8.322,00 base
1. sij 2024.
8.486,00 base
Invalid Date
6.599,00 base
| GODINA | BRUTO MARGINA (%) |
|---|---|
| 2028 est | 20,84 |
| 2027 est | 26,50 |
| 2026 est | 35,33 |
| 2025 est | 65,99 |
| 2024 | 84,86 |
| 2023 | 83,22 |
| 2022 | 80,30 |
| 2021 | 79,49 |
| 2020 | -30,18 |
| 2019 | 1,20 |
| 2018 | 16,80 |
| 2017 | 22,96 |
| 2016 | 17,57 |
| 2015 | 42,34 |
| 2014 | 46,33 |
| 2013 | 63,06 |
| 2012 | 63,64 |
| 2011 | 51,72 |
Medicalgorithmics Revenue
Medicalgorithmics dionica promet, EBIT, dobit
3 godine
5 godina
10 godina
25 godina
Max
Prihod
EBIT
Dobit
Details
Date
Prihod
EBIT
Dobit
1. sij 2011.
5,80 mil. PLN
3,10 mil. PLN
3,00 mil. PLN
1. sij 2012.
11,00 mil. PLN
7,10 mil. PLN
7,40 mil. PLN
1. sij 2013.
15,70 mil. PLN
10,00 mil. PLN
10,90 mil. PLN
1. sij 2014.
29,71 mil. PLN
13,89 mil. PLN
14,53 mil. PLN
1. sij 2015.
49,33 mil. PLN
21,13 mil. PLN
13,93 mil. PLN
1. sij 2016.
127,92 mil. PLN
18,87 mil. PLN
40,11 mil. PLN
1. sij 2017.
203,35 mil. PLN
41,82 mil. PLN
25,54 mil. PLN
1. sij 2018.
199,40 mil. PLN
25,40 mil. PLN
14,42 mil. PLN
1. sij 2019.
173,87 mil. PLN
55.000,00 PLN
4,28 mil. PLN
1. sij 2020.
111,73 mil. PLN
−38,46 mil. PLN
−12,92 mil. PLN
1. sij 2021.
48,35 mil. PLN
12,13 mil. PLN
−180,64 mil. PLN
1. sij 2022.
62,72 mil. PLN
16,02 mil. PLN
−11,86 mil. PLN
1. sij 2023.
43,10 mil. PLN
552.000,00 PLN
−578.000,00 PLN
1. sij 2024.
24,00 mil. PLN
−13,86 mil. PLN
−16,08 mil. PLN
Invalid Date
30,87 mil. PLN
−10,22 mil. PLN
−10,90 mil. PLN
Medicalgorithmics Margins
Medicalgorithmics Aktie marže
Medicalgorithmics analiza marži pokazuje bruto maržu, EBIT maržu, kao i profitnu maržu od Medicalgorithmics. EBIT marža (EBIT/Promet) pokazuje koliko posto prometa ostaje kao operativni dobitak. Profitna marža pokazuje koliko posto prometa od Medicalgorithmics ostaje.
3 godine
5 godina
10 godina
25 godina
Max
Bruto marža
EBIT marža
Marža dobiti
Details
Date
Bruto marža
EBIT marža
Marža dobiti
1. sij 2011.
51,72 %
53,45 %
51,72 %
1. sij 2012.
63,64 %
64,55 %
67,27 %
1. sij 2013.
63,06 %
63,69 %
69,43 %
1. sij 2014.
46,33 %
46,75 %
48,89 %
1. sij 2015.
42,34 %
42,83 %
28,23 %
1. sij 2016.
17,57 %
14,75 %
31,35 %
1. sij 2017.
22,96 %
20,57 %
12,56 %
1. sij 2018.
16,80 %
12,74 %
7,23 %
1. sij 2019.
1,20 %
0,03 %
2,46 %
1. sij 2020.
−30,18 %
−34,42 %
−11,56 %
1. sij 2021.
79,49 %
25,09 %
−373,61 %
1. sij 2022.
80,30 %
25,55 %
−18,91 %
1. sij 2023.
83,22 %
1,28 %
−1,34 %
1. sij 2024.
84,86 %
−57,76 %
−67,00 %
Invalid Date
84,86 %
−33,10 %
−35,33 %
Medicalgorithmics Analiza dionica
Što radi Medicalgorithmics? Medicalgorithmics je jedna od najpopularnijih tvrtki na Eulerpool.com.
Česta pitanja o Medicalgorithmics dionici
Na Eulerpool-u možete pronaći potpuni povijesni razvoj Medicalgorithmics tvrtke Gross Profit od 2006. – s godišnjim vrijednostima, grafikonima i detaljnim analizama.
Income Statement — Medicalgorithmics
Aktiensparpläne nude atraktivnu mogućnost za investitore za dugoročno stvaranje imovine. Jedna od glavnih prednosti je tzv. efekt prosječenja troškova: investirajući redovito fiksni iznos u dionice ili dioničke fondove, automatski se kupuje više udjela kada su cijene niske, a manje kada su visoke. To može dovesti do povoljnijeg prosječnog cijene po udjelu tijekom vremena. Osim toga, Aktiensparpläne omogućavaju i malim investitorima pristup skupim dionicama, jer mogu sudjelovati već s malim iznosima. Redovita investicija također promiče discipliniranu strategiju ulaganja i pomaže izbjeći emocionalne odluke, poput impulzivne kupnje ili prodaje. Pored toga, investitori profitiraju od potencijalnog povećanja vrijednosti dionica kao i od isplata dividendi koje mogu biti reinvestirane, što pojačava učinak kamatnog kamata i time rast uloženog kapitala.
All Key Metrics — Medicalgorithmics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Temeljni kapital
- Obveze
- Dugovanje
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth